Meeting
2014 ASCO Annual Meeting
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
Authors
Joel W. Neal
Stanford Cancer Institute, Stanford, CA
Joel W. Neal , Heather A. Wakelee , Josephine Louella Feliciano , Sarah B. Goldberg , Daniel Morgensztern , Millie Snigdha Das , Rebecca Suk Heist , Inga Tolin Lennes , Alona Muzikansky , Martin J. Edelman , Scott N. Gettinger , Lecia V. Sequist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00977470
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8088)
DOI
10.1200/jco.2014.32.15_suppl.8088
Abstract #
8088
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).
First Author: Howard Jack West
Poster
2018 ASCO Annual Meeting
Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.
First Author: Chul Kim
First Author: Karen L. Reckamp
Poster
2014 ASCO Annual Meeting
Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).
First Author: Primo Lara Jr.